Oncology: Prostate
Todd Morgan, MD
University of Michigan
Heather Cheng, MD, PHD (she/her/hers)
MD, PhD
University of Washington and Fred Hutchinson Cancer Center
Leonard Gomella, MD
Professor And Chair, Thomas Jefferson University
Sidney Kimmel Cancer Center, Thomas Jefferson University
Course Description: There has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer over the last several years. While the clinical impact of the breast cancer gene (BRCA1/2) mutations has been well established in the setting of breast and ovarian cancer with critical implications for treatment (e.g., PARP inhibition), urologists are now confronted with questions surrounding screening guidelines in men at high genetic risk of prostate cancer, genetic testing in men with localized or metastatic prostate cancer, and the impact on treatment decisions in men with prostate cancer and inherited DNA damage repair gene mutations (present in >10% of men with metastatic disease). This course will cover the state of the art in genetic testing and discuss the practical impact on patient care, including pivotal clinical trial data. Urologists will leave this course with a clear understanding of how to translate these latest scientific advances into their routine clinical practice, improving the care of these men who are at a markedly elevated risk of progression and death from prostate cancer.